Erschienen in:
01.03.2009 | Clinical study - patient study
Long-term survival in primary CNS lymphoma treated by high-dose methotrexate monochemotherapy: role of STAT6 activation as prognostic determinant
verfasst von:
Seung-Ho Yang, Kun Soo Lee, Il Sup Kim, Jae Taek Hong, Jae Hoon Sung, Byung Chul Son, Sang Won Lee, Yong-Kil Hong
Erschienen in:
Journal of Neuro-Oncology
|
Ausgabe 1/2009
Einloggen, um Zugang zu erhalten
Abstract
We report a single-center experience of 16 immunocompetent patients diagnosed with primary central nervous system lymphoma and treated with monochemotherapy with high-dose methotrexate (MTX) and deferred radiotherapy. MTX was given at a dose of 8.0 g/m2 for induction and at a dose of 3.5–8.0 g/m2 for maintenance. There were eight complete responses (CR), one partial response, one stable disease, and six patients whose tumors progressed in spite of the chemotherapy. At final follow-up, five of five CRs were alive and well without radiotherapy, with median follow-up of 26 months. Overall survival in eight non-CRs treated with the subsequent radiotherapy was 36 months. In the immunohistochemical study, STAT6 was positively expressed in 8 out of 13 cases. They included all non-CRs and two CRs. This observation suggests that STAT6 expression can be used as a prognostic determinant for MTX chemotherapy.